@FiercePharma: AstraZeneca pitches social-media rules to FDA. Report | Follow @FiercePharma
> Mallinckrodt has launched its generic version of Cephalon's Actiq, an opioid analgesic indicated only for the management of breakthrough cancer pain in patients 16 years of age and older with malignancies. Release
> With FDA approval in hand for its painkiller Exalgo, Covidien plans to beef up its sales force to handle the launch. Report
> A California jury declined to hold Botox maker Allergan liable in the death of a 7-year-old Texas girl being treated for cerebral palsy, finding the company's warning labels adequate. Report
> Roche's top-selling drug MabThera has been recommended by the U.K.'s cost-effectiveness watchdog for use in rheumatoid arthritis patients. Report
> At least a half-dozen House Democrats who voted against the health-care bill say they are now undecided, and President Barack Obama says he is willing to embrace several Republican ideas to collect more votes. Report
> Danish drugmaker Novo Nordisk has secured a one-year contract with the U.S. Department of Veterans Affairs to become the primary supplier of insulin for American war veterans. Report
Biotech News
@FierceBiotech: The world's most expensive drugs. Report | Follow @FierceBiotech
@JohnCFierce: Who needs poker when you can gamble on biotech stocks? Follow @JohnCFierce
> NicOx gains new partner on glaucoma program. Story
> Yesterday's announcement that Archimedes Pharma had snared a $100 million bankroll from two big investors--Warburg Pincus and Novo A/S--leaves the company with a sizeable sum to roll out its new nasal spray product for breakthrough cancer pain. Report
> PTC Therapeutics' lead drug ataluren failed a Phase IIb trial, flunking a test of its ability to improve the physical performance of patients with a rare genetic disorder. Item
> BMS inks $413 million pain pact with Allergan. Story
> Medivation announced this morning that its pivotal, late-stage trial for the Alzheimer's drug Dimebon failed to hit its co-primary and secondary endpoints. Article
> AstraZeneca outlines deep cuts in global R&D ops. Report
And Finally ... A diet high in fruits, vegetables and healthful grains may be associated with higher ovarian cancer survival rates. Report